Despite the limited efficacy of immune checkpoint inhibitor (ICI) monotherapy for EGFR-mutant NSCLC [4-6], ongoing discussions have explored the potential advantages of incorporating ICIs into platinum-based combination therapies following EGFR-TKI resistance. Here, EGFR is linked to non-small cell lung carcinoma.